The phenomenon is likely driven by the systemic inflammation inherent in both COVID-19 and mucormycosis, where the inflammatory milieu, characterized by elevated CRP and D-dimer in COVID-19, exacerbates platelet production [41–43].Clinically, these findings suggest that while thrombocytopenia may be a marker of severe COVID-19 [44,45], higher or normal platelet counts, particularly in the context of elevated inflammatory markers like CRP and D-dimer [41,42], in a patient with suspected mucormycosis and a history of COVID-19 should not rule out the diagnosis. The gene discussed is CRP; the disease is Zygomycosis.